Literature DB >> 28750425

Emerging Therapeutic Strategies in the Treatment of Hemophilia A.

Vincent Muczynski1, Olivier D Christophe1, Cécile V Denis1, Peter J Lenting1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28750425     DOI: 10.1055/s-0037-1604053

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


× No keyword cloud information.
  5 in total

1.  Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.

Authors:  Benjamin J Samelson-Jones; Jonathan D Finn; Lindsey A George; Rodney M Camire; Valder R Arruda
Journal:  JCI Insight       Date:  2019-06-20

Review 2.  Non-factor replacement therapy for haemophilia: a current update.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2018-02-14       Impact factor: 3.443

Review 3.  Laboratory monitoring of hemophilia A treatments: new challenges.

Authors:  Peter J Lenting
Journal:  Blood Adv       Date:  2020-05-12

4.  Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII).

Authors:  Jane R Wells; Adam Gater; Chris Marshall; Theo Tritton; Parth Vashi; Sophia Kessabi
Journal:  Patient       Date:  2019-12       Impact factor: 3.883

5.  Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors.

Authors:  Elena Barbon; Gabriel Ayme; Federico Mingozzi; Peter J Lenting; Amel Mohamadi; Jean-François Ottavi; Charlotte Kawecki; Caterina Casari; Sebastien Verhenne; Solenne Marmier; Laetitia van Wittenberghe; Severine Charles; Fanny Collaud; Cecile V Denis; Olivier D Christophe
Journal:  EMBO Mol Med       Date:  2020-03-11       Impact factor: 12.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.